CELC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CE

Mkt Cap

$2.77B

Volume

2.53M

Next Earnings

November 11th

Loading chart

CE

CELCCelcuity Inc. Common Stock

CELC

Pay with—

Available Balance0.00

CE

Mkt Cap

$2.95B

Volume

2.53M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

New Strong Sell Stocks for October 14thZacks has added three stocks to its Strong Sell list: adidas AG with a 5.1% downward earnings revision, Celcuity Inc. with a 15.3% downward revision, and Collective Mining Ltd. with a 31.8% downward earnings revision over the last 60 days.Zacks Investment Research · Oct 14, 2026

Why Celcuity Stock Was a Winner on WednesdayCelcuity stock gained 2.8% on Wednesday as the biotech company launched its first FDA-approved drug, Revtorpyk, for HR+/HER2 breast cancer treatment. The company also introduced support services for patients and physicians. The stock outperformed the broader market, which saw the S&P 500 decline 0.3%.The Motley Fool · Sep 30, 2026

NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the FirmLaw firm Kessler Topaz Meltzer & Check is investigating Celcuity Inc. for potential securities law violations following the company's announcement of a delayed drug launch for its FDA-approved breast cancer therapy Revtorpyk. The delayed launch timeline, announced on July 14, 2026, fell short of analyst expectations and triggered a 17% stock price decline. The firm is encouraging investors who suffered losses to contact them regarding potential legal rights.GlobeNewswire Inc. · Jul 29, 2026

CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the FirmLaw firm Bragar Eagel & Squire is investigating Celcuity Inc. for potential securities violations following the company's announcement of FDA approval for breast cancer therapy Revtorpyk with a delayed commercial launch in late Q3 2026. The delayed timeline, contrary to analyst expectations, triggered a 17.6% stock price decline on July 15, 2026.GlobeNewswire Inc. · Jul 21, 2026

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast CancerCelcuity announced FDA approval of REVTORPYK (gedatolisib), the first pan-PI3K and mTORC1/2 inhibitor, for treating HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutations. In the Phase 3 VIKTORIA-1 trial, the drug reduced disease progression or death risk by 76% when combined with palbociclib and fulvestrant, and 67% with fulvestrant alone. Commercial launch is anticipated in late Q3 2026.GlobeNewswire Inc. · Jul 14, 2026

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032Celcuity Inc., a clinical-stage biotechnology company, announced the pricing of an upsized $500 million convertible senior notes offering due 2032, increased from the previously announced $400 million. The company plans to use net proceeds of approximately $484.3 million to repay Oxford Finance debt and fund working capital, clinical trials, and R&D. The convertible notes carry a 0.250% interest rate with a conversion price of approximately $124.53 per share, representing a 40% premium to the stock price on June 3, 2026.GlobeNewswire Inc. · Jun 4, 2026

Why Celcuity Stock Popped on MondayCelcuity stock rose nearly 4% after analyst Silvan Turkcan from Citizens initiated coverage with a 'market outperform' rating and $150 price target. The bullish outlook centers on gedatolisib, the company's investigational breast cancer drug, which is less than two months away from FDA review completion. The analyst highlighted the drug's potential for approval in multiple indications beyond breast cancer, which could significantly increase its value.The Motley Fool · Apr 27, 2026

Why Celcuity Stock Popped TodayCelcuity stock rose over 4% after releasing its 2025 financial results, beating analyst expectations with a narrower-than-expected net loss of $0.73 per share versus the projected $1.05. The clinical-stage biotech, which has no revenue, significantly improved its cash position to $166 million from $22.5 million at end-2024, providing substantial runway. The company is also anticipating phase 3 trial results for gedatolisib in advanced breast cancer treatment in Q2.The Motley Fool · Mar 27, 2026

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer DrugDeerfield Management Company increased its stake in Celcuity by 980,470 shares (worth $80.6 million) in Q4, bringing its total position to $170.95 million. Celcuity's stock has surged 1,040% over the past year as the FDA accepted its new drug application for gedatolisib in breast cancer treatment with a decision date of July 17, 2026.The Motley Fool · Mar 13, 2026

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical OncologyCelcuity announced publication of Phase 3 VIKTORIA-1 trial results showing gedatolisib combined with palbociclib and fulvestrant reduced disease progression or death risk by 76% in HR+/HER2- advanced breast cancer patients with PIK3CA wild-type mutations. The FDA has granted Priority Review for gedatolisib's New Drug Application with a decision expected by July 17, 2026.GlobeNewswire Inc. · Mar 9, 2026

to start trading

CE

CELCCelcuity Inc. Common Stock

CELC

Pay with—

Available Balance0.00

Your PositionYou don't own any CELC yet.

Related Tickers

Earnings